Acquisition of APIRx
For personal use only
Acquisition of APIRx Pharmaceuticals USA, LLC
Progress of existing Incannex development programs will not be affected
by the addition of new projects resulting from the APIRx acquisition.
Binding share purchase agreement executed
to acquire 100% of APIRx Pharmaceutical
USA, LLC '(APIRX').
APIRX has 22 active clinical and
pre-clinical research and development
projects underpinned by 19 granted
and 23 pending patents.
Subject to shareholder vote at Extraordinary
General Meeting In June 2022.
Incannex
-
Drug candidates are expertly designed to target
irritable bowel syndrome, addiction disorders,
spasticity and pain in multiple sclerosis, nausea
and vomiting in chemotherapy, inflammatory
bowel disease, periodontal disease and
gingivitis, skin conditions, ophthalmic conditions,
dementia, Parkinson's disease, restless legs
syndrome, among others.
Acquisition of APIRx made by all scrip
transaction of 218M IHL shares at VWAP
calculation of approx. $A0.573c per share
(approx. US$10.05 per ADS).
Shareholder Presentation
4View entire presentation